| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99284 |
Emergency department visit for the evaluation and management, high severity |
168,001 |
143,108 |
$70.97M |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
56,290 |
48,248 |
$43.48M |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
596,543 |
480,956 |
$29.16M |
| J9271 |
Injection, pembrolizumab, 1 mg |
2,989 |
2,284 |
$28.96M |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
28,651 |
24,881 |
$22.88M |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
74,551 |
66,461 |
$20.63M |
| 77386 |
|
21,968 |
1,941 |
$14.05M |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
267,242 |
220,241 |
$13.59M |
| G0378 |
Hospital observation service, per hour |
55,687 |
23,096 |
$13.33M |
| J9299 |
Injection, nivolumab, 1 mg |
1,407 |
974 |
$11.38M |
| 70553 |
Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences |
11,822 |
10,774 |
$10.32M |
| J1745 |
Injection, infliximab, excludes biosimilar, 10 mg |
2,201 |
1,886 |
$9.51M |
| 93306 |
Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete |
13,544 |
11,854 |
$8.19M |
| J1561 |
Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg |
4,061 |
2,230 |
$7.20M |
| 71260 |
Computed tomography, thorax, diagnostic; with contrast material |
14,392 |
12,471 |
$6.96M |
| C1713 |
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) |
8,577 |
6,509 |
$6.70M |
| 96413 |
Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance |
28,927 |
16,746 |
$6.44M |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
102,677 |
85,179 |
$6.36M |
| 80053 |
Comprehensive metabolic panel |
361,020 |
268,114 |
$6.35M |
| J3380 |
Injection, vedolizumab, intravenous, 1 mg |
989 |
911 |
$6.03M |
| 71275 |
Computed tomographic angiography, chest, with contrast material |
11,778 |
10,080 |
$5.83M |
| 70450 |
Computed tomography, head or brain; without contrast material |
21,203 |
17,597 |
$5.75M |
| 70496 |
|
8,741 |
7,306 |
$5.51M |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
38,541 |
18,731 |
$5.45M |
| 78815 |
Positron emission tomography (PET) for limited area imaging |
3,644 |
3,284 |
$4.91M |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
31,358 |
27,039 |
$4.70M |
| 96375 |
Therapeutic injection; each additional sequential IV push |
54,415 |
40,332 |
$4.63M |
| 43239 |
Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple |
6,694 |
6,206 |
$4.53M |
| G0482 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed |
28,679 |
20,598 |
$4.27M |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
86,167 |
55,951 |
$4.25M |
| 70498 |
|
8,204 |
6,920 |
$4.16M |
| 72125 |
Computed tomography, cervical spine; without contrast material |
10,817 |
9,185 |
$4.16M |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
6,952 |
6,063 |
$4.15M |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
30,748 |
26,758 |
$4.12M |
| 71045 |
Radiologic examination, chest; single view |
47,453 |
38,586 |
$4.00M |
| J0585 |
Injection, onabotulinumtoxina, 1 unit |
5,097 |
4,113 |
$3.96M |
| 99291 |
Critical care, evaluation and management of the critically ill patient, first 30-74 minutes |
2,977 |
2,403 |
$3.47M |
| 69436 |
Tympanostomy (requiring insertion of ventilating tube), general anesthesia |
3,895 |
3,592 |
$3.45M |
| 42820 |
Tonsillectomy and adenoidectomy; younger than age 12 |
2,812 |
2,629 |
$3.45M |
| 74174 |
|
4,320 |
3,600 |
$3.39M |
| 71046 |
Radiologic examination, chest; 2 views |
36,349 |
31,671 |
$3.34M |
| 36415 |
Collection of venous blood by venipuncture |
560,344 |
346,994 |
$3.28M |
| 96361 |
Intravenous infusion, hydration; each additional hour |
30,821 |
22,328 |
$3.23M |
| 93975 |
|
8,889 |
8,026 |
$3.17M |
| 41899 |
Unlisted procedure, dentoalveolar structures |
2,689 |
2,279 |
$3.14M |
| 76705 |
Ultrasound, abdominal, real time with image documentation; limited |
15,559 |
14,036 |
$3.14M |
| G0483 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed |
19,708 |
17,199 |
$3.11M |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
272,515 |
215,037 |
$3.07M |
| C1776 |
Joint device (implantable) |
1,188 |
967 |
$3.01M |
| 70551 |
Magnetic resonance imaging, brain; without contrast material |
4,209 |
3,823 |
$2.80M |
| 87633 |
Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets |
9,178 |
8,445 |
$2.79M |
| 70491 |
|
5,515 |
4,750 |
$2.74M |
| 95810 |
Polysomnography; sleep staging with 4 or more additional parameters |
2,655 |
2,269 |
$2.74M |
| 74183 |
|
3,359 |
2,981 |
$2.68M |
| 72131 |
|
7,695 |
6,507 |
$2.67M |
| 71250 |
|
8,721 |
7,177 |
$2.53M |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
40,790 |
12,733 |
$2.46M |
| 72128 |
|
6,565 |
5,507 |
$2.40M |
| 76770 |
|
9,880 |
9,232 |
$2.38M |
| 95715 |
|
2,458 |
1,620 |
$2.33M |
| 70486 |
|
6,210 |
5,454 |
$2.26M |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
41,079 |
31,273 |
$2.20M |
| 96366 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour |
12,469 |
7,344 |
$2.17M |
| 49083 |
|
3,457 |
1,575 |
$2.12M |
| Q5107 |
Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg |
804 |
342 |
$2.12M |
| G0390 |
Trauma response team associated with hospital critical care service |
1,337 |
1,005 |
$2.05M |
| 73630 |
|
20,589 |
14,819 |
$2.03M |
| 93325 |
|
11,425 |
10,405 |
$1.99M |
| C1889 |
Implantable/insertable device, not otherwise classified |
7,630 |
6,465 |
$1.98M |
| 77412 |
|
9,154 |
1,053 |
$1.97M |
| 47562 |
|
743 |
637 |
$1.95M |
| 45380 |
Colonoscopy, flexible; with biopsy, single or multiple |
2,963 |
2,684 |
$1.93M |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
31,709 |
28,038 |
$1.85M |
| 72197 |
|
2,213 |
1,987 |
$1.78M |
| 93304 |
|
6,139 |
5,526 |
$1.75M |
| 84443 |
Thyroid stimulating hormone (TSH) |
106,780 |
96,884 |
$1.66M |
| 87631 |
|
12,634 |
11,918 |
$1.66M |
| 76830 |
Ultrasound, transvaginal |
8,826 |
7,731 |
$1.65M |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
14,967 |
10,322 |
$1.61M |
| 73610 |
|
17,636 |
13,680 |
$1.59M |
| 36430 |
|
4,028 |
2,388 |
$1.58M |
| 67311 |
|
1,115 |
1,027 |
$1.57M |
| J2505 |
Injection, pegfilgrastim, 6 mg |
472 |
321 |
$1.54M |
| J9312 |
Injection, rituximab, 10 mg |
306 |
200 |
$1.51M |
| 93303 |
Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study |
3,685 |
3,115 |
$1.50M |
| 73562 |
|
15,122 |
11,688 |
$1.47M |
| 92507 |
Treatment of speech, language, voice, communication, and/or auditory processing disorder |
19,749 |
6,532 |
$1.46M |
| 87637 |
Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV |
16,945 |
15,717 |
$1.44M |
| 95816 |
|
4,479 |
4,281 |
$1.43M |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
41,599 |
37,735 |
$1.43M |
| 59025 |
Fetal non-stress test |
8,373 |
4,538 |
$1.42M |
| 73130 |
|
15,203 |
11,997 |
$1.36M |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
41,079 |
37,386 |
$1.35M |
| 76816 |
Ultrasound, pregnant uterus, real time with image documentation, follow-up |
7,916 |
6,952 |
$1.33M |
| Q5103 |
Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg |
510 |
431 |
$1.32M |
| 74018 |
|
14,522 |
12,260 |
$1.30M |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
16,254 |
14,463 |
$1.29M |
| 72148 |
Magnetic resonance imaging, lumbar spine; without contrast material |
1,742 |
1,618 |
$1.29M |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
33,642 |
31,018 |
$1.27M |
| 77301 |
|
979 |
872 |
$1.25M |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
19,084 |
14,010 |
$1.24M |
| 96415 |
|
7,617 |
4,731 |
$1.24M |
| 76811 |
Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed |
4,730 |
4,292 |
$1.23M |
| Q3014 |
Telehealth originating site facility fee |
47,176 |
40,424 |
$1.23M |
| 36591 |
|
26,143 |
12,352 |
$1.22M |
| 70543 |
|
1,330 |
1,219 |
$1.22M |
| 77334 |
|
2,320 |
1,747 |
$1.22M |
| 85027 |
|
155,484 |
123,556 |
$1.18M |
| 73110 |
|
12,534 |
9,626 |
$1.16M |
| 88185 |
|
3,578 |
3,009 |
$1.16M |
| 73030 |
|
12,256 |
9,450 |
$1.14M |
| 94060 |
|
5,876 |
5,095 |
$1.13M |
| 73590 |
|
12,253 |
9,818 |
$1.11M |
| 76642 |
|
7,733 |
5,891 |
$1.10M |
| 54161 |
|
871 |
780 |
$1.08M |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
89,007 |
62,332 |
$1.04M |
| 95951 |
|
1,411 |
597 |
$1.00M |
| 93971 |
|
4,943 |
4,420 |
$990K |
| 93321 |
|
7,057 |
6,458 |
$988K |
| 77336 |
|
5,889 |
2,492 |
$986K |
| 64488 |
|
969 |
735 |
$980K |
| 44970 |
|
536 |
437 |
$975K |
| J9035 |
Injection, bevacizumab, 10 mg |
213 |
133 |
$967K |
| 73721 |
Magnetic resonance imaging, any joint of lower extremity; without contrast material |
1,349 |
1,231 |
$961K |
| 74178 |
|
949 |
856 |
$956K |
| 72141 |
|
1,360 |
1,247 |
$953K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
42,859 |
39,682 |
$940K |
| 72156 |
|
967 |
865 |
$940K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
77,294 |
56,408 |
$930K |
| 94010 |
|
9,983 |
8,321 |
$929K |
| 72100 |
|
7,952 |
7,110 |
$925K |
| 75561 |
|
1,218 |
1,097 |
$907K |
| 45385 |
Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) |
1,490 |
1,313 |
$900K |
| 84484 |
|
39,693 |
28,195 |
$897K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
13,999 |
11,290 |
$892K |
| 72158 |
|
975 |
874 |
$871K |
| 73080 |
|
10,017 |
8,102 |
$864K |
| 88307 |
|
5,600 |
4,486 |
$861K |
| C1769 |
Guide wire |
13,085 |
10,360 |
$860K |
| 96376 |
|
12,449 |
9,835 |
$852K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
19,116 |
16,199 |
$838K |
| 96417 |
|
6,578 |
4,150 |
$824K |
| 87902 |
|
3,747 |
3,432 |
$807K |
| 43264 |
|
697 |
580 |
$795K |
| 19083 |
|
534 |
470 |
$793K |
| 76536 |
|
5,136 |
4,776 |
$790K |
| 97530 |
Therapeutic activities, direct patient contact, each 15 minutes |
17,767 |
6,662 |
$781K |
| J2350 |
Injection, ocrelizumab, 1 mg |
45 |
38 |
$778K |
| 87522 |
Neg quan hep c or qual rna |
18,286 |
16,095 |
$771K |
| 43235 |
|
1,864 |
1,618 |
$762K |
| 36561 |
|
488 |
435 |
$755K |
| 93308 |
|
3,582 |
3,166 |
$753K |
| A9585 |
Injection, gadobutrol, 0.1 ml |
23,446 |
19,691 |
$751K |
| 87536 |
|
10,785 |
9,942 |
$748K |
| 73700 |
|
1,981 |
1,611 |
$747K |
| 62323 |
|
956 |
878 |
$745K |
| 76817 |
Ultrasound, pregnant uterus, real time with image documentation, transvaginal |
5,525 |
4,335 |
$742K |
| 64493 |
|
901 |
748 |
$741K |
| 81229 |
|
1,011 |
817 |
$739K |
| 73090 |
|
9,159 |
7,451 |
$738K |
| Q5118 |
Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg |
468 |
208 |
$737K |
| 80061 |
Lipid panel |
57,174 |
52,750 |
$725K |
| J0185 |
Injection, aprepitant, 1 mg |
3,151 |
2,006 |
$717K |
| 82805 |
|
14,122 |
11,254 |
$715K |
| 78452 |
Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress |
1,038 |
646 |
$711K |
| 73552 |
|
8,727 |
6,887 |
$701K |
| D7140 |
Extraction, erupted tooth or exposed root |
1,905 |
1,236 |
$686K |
| 58571 |
|
260 |
176 |
$685K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
76,022 |
69,567 |
$685K |
| 76857 |
|
2,805 |
2,498 |
$674K |
| 97140 |
Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) |
15,054 |
5,532 |
$665K |
| 96367 |
|
6,351 |
3,858 |
$664K |
| 99281 |
Emergency department visit for the evaluation and management, self-limited or minor |
8,808 |
7,372 |
$658K |
| J7050 |
Infusion, normal saline solution, 250 cc |
62,901 |
28,842 |
$638K |
| 77338 |
|
1,131 |
917 |
$629K |
| 76700 |
Ultrasound, abdominal, real time with image documentation; complete |
2,426 |
2,121 |
$627K |
| 83605 |
|
44,915 |
36,594 |
$620K |
| J9355 |
Injection, trastuzumab, excludes biosimilar, 10 mg |
138 |
92 |
$619K |
| 20680 |
|
377 |
309 |
$617K |
| 88304 |
|
9,172 |
8,036 |
$616K |
| 72040 |
|
5,469 |
4,691 |
$609K |
| J2506 |
Injection, pegfilgrastim, excludes biosimilar, 0.5 mg |
224 |
153 |
$609K |
| 77300 |
|
1,788 |
1,385 |
$597K |
| 93970 |
|
2,153 |
1,940 |
$585K |
| P9016 |
Red blood cells, leukocytes reduced, each unit |
1,992 |
1,516 |
$582K |
| 88341 |
|
3,898 |
3,134 |
$576K |
| 76000 |
|
4,751 |
3,889 |
$575K |
| C1726 |
Catheter, balloon dilatation, non-vascular |
2,720 |
2,191 |
$574K |
| 11042 |
Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm |
2,713 |
1,822 |
$573K |
| 87507 |
|
2,189 |
1,985 |
$572K |
| 76815 |
Ultrasound, pregnant uterus, real time with image documentation, limited |
3,985 |
3,380 |
$568K |
| 64615 |
|
2,734 |
2,378 |
$555K |
| 83735 |
|
77,938 |
53,129 |
$553K |
| 87389 |
Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies |
34,431 |
31,472 |
$535K |
| 93017 |
|
1,978 |
1,719 |
$535K |
| 73060 |
|
6,602 |
5,488 |
$531K |
| 73502 |
|
7,291 |
5,897 |
$531K |
| 76805 |
Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation |
2,334 |
2,098 |
$527K |
| 83690 |
|
45,952 |
38,255 |
$525K |
| 20610 |
|
2,073 |
1,788 |
$516K |
| C9803 |
Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
57,864 |
47,501 |
$514K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
55,584 |
47,539 |
$504K |
| 94726 |
|
4,707 |
4,205 |
$501K |
| 86480 |
|
9,833 |
9,015 |
$498K |
| 88342 |
|
7,121 |
6,025 |
$497K |
| 31624 |
|
731 |
587 |
$496K |
| 73560 |
|
5,628 |
3,890 |
$493K |
| 52356 |
|
182 |
146 |
$485K |
| 77066 |
Tomosynthesis, mammo |
4,393 |
3,785 |
$484K |
| 51798 |
|
5,589 |
5,249 |
$482K |
| 73120 |
|
4,966 |
4,518 |
$481K |
| C1874 |
Stent, coated/covered, with delivery system |
335 |
278 |
$473K |
| A9552 |
Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries |
4,726 |
3,747 |
$472K |
| 72170 |
|
5,820 |
4,753 |
$472K |
| 84439 |
|
52,602 |
48,515 |
$471K |
| 77290 |
|
962 |
589 |
$466K |
| 10060 |
|
2,489 |
2,236 |
$457K |
| 73221 |
|
642 |
586 |
$453K |
| 96411 |
|
3,035 |
2,032 |
$452K |
| 76870 |
|
2,374 |
2,144 |
$452K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
13,842 |
13,176 |
$449K |
| 95700 |
|
2,743 |
2,515 |
$447K |
| 78816 |
|
267 |
238 |
$441K |
| 86803 |
|
33,516 |
30,383 |
$440K |
| 86850 |
|
33,812 |
27,626 |
$438K |
| 93320 |
|
2,269 |
2,016 |
$437K |
| 94729 |
|
4,636 |
4,257 |
$432K |
| 81001 |
|
60,858 |
52,680 |
$429K |
| 93225 |
|
2,218 |
1,953 |
$427K |
| 97112 |
Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination |
5,746 |
1,603 |
$421K |
| 83880 |
|
14,152 |
12,070 |
$419K |
| 20553 |
|
1,739 |
1,623 |
$418K |
| 80074 |
|
9,167 |
8,316 |
$417K |
| 70480 |
|
1,344 |
1,246 |
$417K |
| 97161 |
|
6,898 |
5,878 |
$414K |
| 76801 |
|
2,582 |
2,208 |
$402K |
| 87040 |
|
11,837 |
8,768 |
$402K |
| 77067 |
Screening mammography, bilateral, including computer-aided detection |
6,154 |
5,737 |
$400K |
| C1887 |
Catheter, guiding (may include infusion/perfusion capability) |
2,933 |
2,323 |
$395K |
| C1894 |
Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser |
6,677 |
5,319 |
$383K |
| 85610 |
|
76,061 |
61,835 |
$380K |
| 86360 |
|
9,819 |
9,080 |
$376K |
| 95885 |
|
2,509 |
1,878 |
$375K |
| 86140 |
|
52,828 |
46,122 |
$373K |
| 93226 |
|
2,420 |
2,246 |
$366K |
| 75574 |
|
1,091 |
1,015 |
$365K |
| 64494 |
|
918 |
600 |
$361K |
| 76819 |
Fetal biophysical profile; without non-stress testing |
2,027 |
1,571 |
$357K |
| 31575 |
|
1,402 |
1,231 |
$355K |
| A0425 |
Ground mileage, per statute mile |
6,497 |
4,574 |
$354K |
| 77065 |
Tomosynthesis, mammo |
3,693 |
3,119 |
$354K |
| 81003 |
|
87,197 |
71,941 |
$353K |
| 84702 |
|
19,835 |
15,997 |
$353K |
| 36592 |
|
9,042 |
3,307 |
$351K |
| 72082 |
|
3,269 |
2,918 |
$350K |
| 86235 |
|
6,982 |
6,374 |
$349K |
| 95708 |
|
317 |
252 |
$346K |
| 86832 |
|
1,946 |
1,642 |
$343K |
| 84703 |
|
30,047 |
26,139 |
$337K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
18,056 |
16,713 |
$336K |
| 76813 |
|
2,447 |
2,151 |
$335K |
| 74230 |
|
2,534 |
1,993 |
$332K |
| D1120 |
Prophylaxis - child |
828 |
721 |
$332K |
| 90460 |
Immunization administration through 18 years of age via any route, first or only component |
36,211 |
34,960 |
$330K |
| 76942 |
|
2,115 |
1,762 |
$329K |
| 82565 |
|
30,470 |
22,897 |
$327K |
| 86833 |
|
1,916 |
1,636 |
$327K |
| 83970 |
|
9,540 |
8,297 |
$326K |
| 87581 |
|
9,589 |
8,866 |
$326K |
| 76856 |
Ultrasound, pelvic (nonobstetric), real time with image documentation; complete |
1,434 |
1,293 |
$322K |
| 70487 |
|
844 |
746 |
$319K |
| 73564 |
|
2,719 |
1,900 |
$318K |
| C1725 |
Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) |
997 |
828 |
$315K |
| 12001 |
|
2,484 |
2,249 |
$314K |
| 81025 |
|
31,133 |
27,280 |
$313K |
| 87486 |
|
9,702 |
8,861 |
$311K |
| 90677 |
|
6,612 |
6,364 |
$309K |
| 95911 |
|
840 |
787 |
$309K |
| J2704 |
Injection, propofol, 10 mg |
91,326 |
65,563 |
$307K |
| 77295 |
|
187 |
147 |
$305K |
| 45378 |
Colonoscopy, flexible; diagnostic, including collection of specimen(s) |
522 |
457 |
$303K |
| 95886 |
|
2,128 |
1,790 |
$303K |
| 86359 |
|
9,827 |
9,080 |
$302K |
| 82330 |
|
21,032 |
15,943 |
$296K |
| 64635 |
|
302 |
235 |
$294K |
| 93976 |
|
1,506 |
1,360 |
$291K |
| 10005 |
|
509 |
480 |
$286K |
| 90378 |
|
385 |
335 |
$283K |
| 64445 |
|
651 |
511 |
$282K |
| 72157 |
|
292 |
265 |
$281K |
| 95806 |
|
1,499 |
1,362 |
$280K |
| 77080 |
|
2,780 |
2,317 |
$280K |
| 90651 |
|
4,972 |
4,791 |
$279K |
| 74160 |
|
673 |
571 |
$277K |
| 42830 |
|
378 |
354 |
$275K |
| 76825 |
|
762 |
706 |
$273K |
| 52332 |
|
275 |
203 |
$262K |
| 58661 |
|
155 |
121 |
$262K |
| 75565 |
|
906 |
835 |
$261K |
| 95819 |
|
836 |
786 |
$258K |
| 86355 |
|
8,622 |
7,974 |
$258K |
| G0145 |
Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision |
11,732 |
10,542 |
$257K |
| 86357 |
|
8,581 |
7,981 |
$254K |
| 12011 |
|
2,050 |
1,891 |
$252K |
| 91200 |
|
2,266 |
2,078 |
$251K |
| 86900 |
|
34,709 |
28,118 |
$251K |
| 92611 |
|
1,937 |
1,699 |
$250K |
| 86703 |
|
16,773 |
15,005 |
$248K |
| 78830 |
|
262 |
215 |
$246K |
| J7120 |
Ringers lactate infusion, up to 1000 cc |
92,554 |
71,462 |
$246K |
| 82607 |
|
19,819 |
18,350 |
$244K |
| 72050 |
|
1,657 |
1,437 |
$243K |
| 76820 |
|
1,922 |
1,569 |
$243K |
| 72110 |
|
1,429 |
1,279 |
$243K |
| J7030 |
Infusion, normal saline solution , 1000 cc |
50,914 |
34,728 |
$240K |
| 82728 |
|
20,894 |
18,815 |
$240K |
| 99218 |
|
869 |
391 |
$238K |
| 36226 |
|
97 |
77 |
$238K |
| D1206 |
Topical application of fluoride varnish |
796 |
671 |
$236K |
| 76882 |
|
1,600 |
1,383 |
$233K |
| G0481 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed |
2,112 |
1,941 |
$228K |
| G0101 |
Cervical or vaginal cancer screening; pelvic and clinical breast examination |
5,824 |
5,096 |
$227K |
| 93296 |
|
6,056 |
5,584 |
$226K |
| 76937 |
|
4,086 |
3,459 |
$225K |
| 29125 |
|
2,449 |
2,080 |
$224K |
| 72190 |
|
1,985 |
1,700 |
$223K |
| 49650 |
|
92 |
82 |
$222K |
| 85730 |
|
31,011 |
26,663 |
$219K |
| 96409 |
|
2,300 |
974 |
$218K |
| 78306 |
|
511 |
414 |
$217K |
| 73521 |
|
1,797 |
1,644 |
$216K |
| 87624 |
Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types |
7,545 |
6,705 |
$215K |
| 82784 |
|
15,787 |
14,333 |
$213K |
| 87070 |
|
17,022 |
13,967 |
$212K |
| 75635 |
|
452 |
395 |
$212K |
| 87077 |
|
20,115 |
17,160 |
$211K |
| 77387 |
|
1,714 |
211 |
$211K |
| 90715 |
|
10,215 |
9,388 |
$209K |
| 95909 |
|
968 |
930 |
$208K |
| 64447 |
|
538 |
415 |
$208K |
| 52000 |
|
466 |
431 |
$207K |
| 80069 |
|
21,248 |
15,046 |
$207K |
| 72070 |
|
2,161 |
1,890 |
$206K |
| 64721 |
|
151 |
132 |
$205K |
| 93880 |
|
961 |
873 |
$205K |
| 97162 |
|
3,560 |
3,001 |
$203K |
| A0427 |
Ambulance service, advanced life support, emergency transport, level 1 (als 1 - emergency) |
3,758 |
2,808 |
$202K |
| 96416 |
|
749 |
415 |
$201K |
| 82542 |
|
6,928 |
5,959 |
$200K |
| 73100 |
|
2,072 |
1,263 |
$196K |
| 84100 |
|
34,879 |
23,897 |
$195K |
| 83516 |
|
12,924 |
11,676 |
$192K |
| 86901 |
|
34,456 |
28,100 |
$190K |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
91,920 |
65,311 |
$190K |
| 70355 |
|
2,503 |
2,112 |
$189K |
| 94618 |
|
1,687 |
1,426 |
$189K |
| 95712 |
|
413 |
382 |
$189K |
| J2997 |
Injection, alteplase recombinant, 1 mg |
1,021 |
650 |
$184K |
| 86780 |
|
14,482 |
13,108 |
$183K |
| 77063 |
Screening digital breast tomosynthesis, bilateral |
6,940 |
6,099 |
$181K |
| 88312 |
|
3,265 |
2,810 |
$181K |
| J7307 |
Etonogestrel (contraceptive) implant system, including implant and supplies |
234 |
206 |
$179K |
| 88173 |
|
2,838 |
2,364 |
$178K |
| 77014 |
|
737 |
107 |
$176K |
| 97165 |
|
3,761 |
3,115 |
$175K |
| 77002 |
|
901 |
823 |
$174K |
| 54150 |
|
311 |
302 |
$174K |
| 64450 |
|
382 |
319 |
$174K |
| 64636 |
|
241 |
182 |
$174K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
4,389 |
4,200 |
$173K |
| 73200 |
|
492 |
402 |
$173K |
| 87340 |
|
16,061 |
14,555 |
$172K |
| 87186 |
|
13,998 |
12,484 |
$169K |
| 93923 |
|
784 |
699 |
$169K |
| 86923 |
|
3,785 |
2,672 |
$169K |
| 74170 |
|
314 |
283 |
$168K |
| 88112 |
|
3,186 |
2,689 |
$168K |
| 72202 |
|
1,691 |
1,598 |
$165K |
| 88184 |
|
3,606 |
3,040 |
$164K |
| 92524 |
|
1,784 |
1,418 |
$161K |
| 87808 |
|
12,653 |
11,614 |
$161K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
8,589 |
7,998 |
$158K |
| 86160 |
|
7,712 |
7,044 |
$158K |
| 80197 |
|
14,515 |
8,508 |
$158K |
| 62322 |
|
414 |
338 |
$157K |
| 73000 |
|
1,766 |
1,475 |
$157K |
| 51600 |
|
631 |
589 |
$155K |
| J0131 |
Injection, acetaminophen, not otherwise specified,10 mg |
14,041 |
12,243 |
$155K |
| 84403 |
|
6,953 |
6,504 |
$154K |
| 12002 |
|
1,129 |
993 |
$153K |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
99,191 |
73,349 |
$152K |
| 72146 |
|
205 |
187 |
$150K |
| 90670 |
|
6,617 |
6,368 |
$149K |
| 86762 |
|
8,378 |
7,432 |
$148K |
| 76818 |
|
756 |
497 |
$147K |
| 82570 |
|
26,342 |
23,665 |
$147K |
| 97016 |
|
5,486 |
1,635 |
$145K |
| 90750 |
|
1,387 |
1,320 |
$145K |
| 93922 |
|
1,150 |
988 |
$144K |
| G0279 |
Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) |
6,690 |
5,569 |
$141K |
| 76827 |
|
754 |
705 |
$140K |
| 74240 |
|
786 |
722 |
$139K |
| 36593 |
|
632 |
415 |
$139K |
| 87081 |
|
14,664 |
13,537 |
$138K |
| 66984 |
Extracapsular cataract removal with insertion of intraocular lens prosthesis |
196 |
139 |
$136K |
| 90686 |
|
20,773 |
19,785 |
$136K |
| C1781 |
Mesh (implantable) |
304 |
250 |
$136K |
| 64642 |
|
806 |
482 |
$135K |
| 27130 |
|
49 |
38 |
$134K |
| 73501 |
|
1,838 |
1,687 |
$134K |
| 87497 |
|
4,011 |
2,292 |
$133K |
| 74019 |
|
1,185 |
1,080 |
$132K |
| 88300 |
|
6,457 |
5,703 |
$130K |
| D1110 |
Prophylaxis - adult |
278 |
192 |
$130K |
| J9305 |
Injection, pemetrexed, not otherwise specified, 10 mg |
377 |
164 |
$129K |
| J0330 |
Injection, succinylcholine chloride, up to 20 mg |
15,006 |
12,225 |
$129K |
| 77012 |
|
558 |
470 |
$129K |
| 80305 |
|
8,685 |
4,597 |
$128K |
| 43762 |
|
419 |
361 |
$128K |
| 86706 |
|
12,333 |
11,254 |
$128K |
| C2617 |
Stent, non-coronary, temporary, without delivery system |
2,369 |
1,894 |
$128K |
| 72192 |
|
504 |
431 |
$127K |
| 82670 |
|
4,841 |
4,511 |
$127K |
| 77076 |
|
623 |
557 |
$127K |
| 96401 |
|
1,489 |
666 |
$125K |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
3,774 |
3,577 |
$125K |
| J0561 |
Injection, penicillin g benzathine, 100,000 units |
705 |
627 |
$124K |
| 82105 |
|
8,132 |
7,305 |
$124K |
| P9047 |
Infusion, albumin (human), 25%, 50 ml |
1,526 |
735 |
$124K |
| C1788 |
Port, indwelling (implantable) |
550 |
486 |
$121K |
| T1019 |
Personal care services, per 15 minutes, not for an inpatient or resident of a hospital, nursing facility, icf/mr or imd, part of the individualized plan of treatment (code may not be used to identify services provided by home health aide or certified nurse assistant) |
687 |
61 |
$121K |
| 21235 |
|
56 |
53 |
$120K |
| 87799 |
|
4,129 |
2,770 |
$120K |
| 95782 |
|
112 |
96 |
$120K |
| 88360 |
|
1,047 |
894 |
$120K |
| 85379 |
|
8,420 |
7,525 |
$119K |
| 97116 |
|
4,698 |
2,518 |
$117K |
| 88313 |
|
2,449 |
2,098 |
$117K |
| D2930 |
Prefabricated stainless steel crown - primary tooth |
510 |
294 |
$116K |
| 83550 |
|
15,824 |
14,483 |
$114K |
| 29075 |
|
789 |
667 |
$114K |
| 92526 |
|
1,634 |
937 |
$112K |
| 80076 |
|
8,997 |
7,685 |
$111K |
| 62270 |
|
390 |
340 |
$111K |
| J9070 |
Cyclophosphamide, 100 mg |
332 |
222 |
$111K |
| 72120 |
|
907 |
831 |
$111K |
| 88172 |
|
2,505 |
2,040 |
$111K |
| J0171 |
Injection, adrenalin, epinephrine, 0.1 mg |
7,368 |
5,756 |
$110K |
| 95811 |
|
127 |
115 |
$110K |
| 95910 |
|
414 |
398 |
$108K |
| 54640 |
|
68 |
64 |
$108K |
| 81374 |
|
1,788 |
1,632 |
$107K |
| 90697 |
|
6,100 |
5,943 |
$107K |
| 85652 |
|
29,607 |
26,580 |
$107K |
| G0008 |
Administration of influenza virus vaccine |
7,932 |
7,246 |
$106K |
| 96450 |
|
377 |
278 |
$106K |
| 78264 |
|
226 |
200 |
$105K |
| 83615 |
|
17,279 |
13,286 |
$104K |
| 83001 |
|
5,631 |
5,263 |
$104K |
| G0379 |
Direct admission of patient for hospital observation care |
977 |
878 |
$104K |
| J7040 |
Infusion, normal saline solution, sterile (500 ml = 1 unit) |
16,302 |
9,573 |
$103K |
| 64415 |
|
218 |
184 |
$101K |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
58,941 |
47,919 |
$99K |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
32,156 |
20,936 |
$98K |
| 95874 |
|
1,268 |
1,145 |
$95K |
| 92610 |
|
952 |
796 |
$95K |
| P9035 |
Platelets, pheresis, leukocytes reduced, each unit |
208 |
95 |
$95K |
| Q0162 |
Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen |
34,070 |
25,761 |
$95K |
| 42821 |
|
58 |
57 |
$94K |
| 86255 |
|
7,730 |
7,129 |
$94K |
| 86704 |
|
8,391 |
7,601 |
$93K |
| 97166 |
|
1,647 |
1,414 |
$92K |
| 25605 |
|
251 |
226 |
$92K |
| J9045 |
Injection, carboplatin, 50 mg |
3,024 |
1,968 |
$92K |
| 86038 |
|
9,010 |
8,256 |
$91K |
| 88331 |
|
1,246 |
940 |
$91K |
| 95716 |
|
84 |
61 |
$91K |
| 86147 |
|
1,969 |
1,791 |
$90K |
| 83655 |
|
7,293 |
6,945 |
$89K |
| 86708 |
|
7,811 |
7,107 |
$89K |
| 97535 |
Self-care/home management training, each 15 minutes |
3,681 |
2,300 |
$89K |
| 77373 |
|
88 |
25 |
$89K |
| 96368 |
|
849 |
530 |
$89K |
| J3420 |
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg |
1,575 |
1,284 |
$88K |
| 20550 |
|
360 |
310 |
$87K |
| 84146 |
|
4,739 |
4,358 |
$87K |
| 93285 |
|
2,130 |
1,827 |
$87K |
| 92609 |
|
1,193 |
457 |
$87K |
| 99152 |
|
7,223 |
6,179 |
$86K |
| J0897 |
Injection, denosumab, 1 mg |
62 |
55 |
$86K |
| P9040 |
Red blood cells, leukocytes reduced, irradiated, each unit |
627 |
342 |
$86K |
| 82947 |
|
13,828 |
10,392 |
$86K |
| 74328 |
|
390 |
324 |
$86K |
| 76001 |
|
408 |
313 |
$86K |
| 62370 |
|
564 |
376 |
$86K |
| 86376 |
|
6,886 |
6,481 |
$85K |
| 82746 |
|
6,987 |
6,468 |
$85K |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
51,934 |
39,873 |
$85K |
| 36224 |
|
12 |
12 |
$84K |
| 87517 |
|
2,402 |
2,212 |
$84K |
| J9267 |
Injection, paclitaxel, 1 mg |
2,443 |
1,252 |
$83K |
| 87483 |
|
285 |
270 |
$83K |
| 87205 |
|
13,372 |
11,544 |
$83K |
| 82378 |
|
3,867 |
3,389 |
$83K |
| C1760 |
Closure device, vascular (implantable/insertable) |
399 |
305 |
$83K |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
50,610 |
40,269 |
$83K |
| 87653 |
|
2,325 |
2,145 |
$82K |
| 80050 |
General health panel |
1,971 |
1,895 |
$82K |
| 86800 |
|
5,279 |
4,943 |
$82K |
| J2785 |
Injection, regadenoson, 0.1 mg |
636 |
566 |
$82K |
| J2710 |
Injection, neostigmine methylsulfate, up to 0.5 mg |
5,764 |
4,385 |
$82K |
| 38222 |
|
171 |
139 |
$81K |
| 29705 |
|
958 |
797 |
$79K |
| J2795 |
Injection, ropivacaine hydrochloride, 1 mg |
7,153 |
5,380 |
$79K |
| 82550 |
|
11,676 |
9,729 |
$78K |
| 78018 |
|
159 |
125 |
$77K |
| J1720 |
Injection, hydrocortisone sodium succinate, up to 100 mg |
3,633 |
2,646 |
$75K |
| 31622 |
|
121 |
104 |
$75K |
| 92523 |
|
618 |
549 |
$75K |
| 93229 |
|
363 |
333 |
$74K |
| 86304 |
|
3,280 |
2,577 |
$73K |
| 96112 |
|
813 |
786 |
$72K |
| 81415 |
|
35 |
27 |
$72K |
| 88175 |
Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer |
3,218 |
2,862 |
$71K |
| 86200 |
|
6,252 |
5,799 |
$70K |
| 74220 |
|
513 |
452 |
$70K |
| 84145 |
|
2,839 |
2,430 |
$70K |
| 29888 |
|
97 |
83 |
$69K |
| 20611 |
|
110 |
96 |
$69K |
| 64495 |
|
187 |
112 |
$68K |
| 82652 |
|
2,546 |
2,372 |
$68K |
| 73140 |
|
906 |
774 |
$67K |
| C1729 |
Catheter, drainage |
1,411 |
1,078 |
$67K |
| J9310 |
Injection, rituximab, 100 mg |
21 |
13 |
$66K |
| 87529 |
|
989 |
921 |
$66K |
| A4648 |
Tissue marker, implantable, any type, each |
989 |
840 |
$66K |
| Q9957 |
Injection, perflutren lipid microspheres, per ml |
856 |
549 |
$66K |
| 82610 |
|
4,187 |
3,869 |
$65K |
| 88302 |
|
1,582 |
1,311 |
$65K |
| 77001 |
|
370 |
326 |
$64K |
| 90472 |
Immunization administration, each additional vaccine (list separately) |
3,639 |
3,404 |
$64K |
| 82077 |
|
3,310 |
2,868 |
$64K |
| J0690 |
Injection, cefazolin sodium, 500 mg |
34,272 |
24,814 |
$63K |
| 87102 |
|
5,122 |
4,308 |
$63K |
| 31652 |
|
66 |
49 |
$62K |
| J1170 |
Injection, hydromorphone, up to 4 mg |
29,456 |
17,233 |
$62K |
| 84156 |
|
17,124 |
14,976 |
$62K |
| 86146 |
|
1,301 |
1,205 |
$62K |
| 84432 |
|
3,710 |
3,329 |
$62K |
| 43259 |
|
102 |
84 |
$61K |
| 83002 |
|
3,703 |
3,496 |
$60K |
| 54163 |
|
68 |
62 |
$60K |
| 87900 |
|
635 |
550 |
$60K |
| J2001 |
Injection, lidocaine hcl for intravenous infusion, 10 mg |
20,906 |
16,699 |
$59K |
| 70250 |
|
541 |
469 |
$59K |
| J8501 |
Aprepitant, oral, 5 mg |
1,902 |
1,675 |
$59K |
| 49591 |
|
50 |
42 |
$59K |
| 47000 |
|
66 |
53 |
$59K |
| 62328 |
|
74 |
65 |
$58K |
| 89051 |
|
6,155 |
3,912 |
$58K |
| 95004 |
Percutaneous tests with allergenic extracts, immediate type reaction |
301 |
292 |
$58K |
| J1756 |
Injection, iron sucrose, 1 mg |
1,523 |
687 |
$58K |
| P9612 |
Catheterization for collection of specimen, single patient, all places of service |
4,292 |
3,323 |
$58K |
| 84600 |
|
2,943 |
2,438 |
$57K |
| 87088 |
|
6,497 |
5,980 |
$57K |
| 86003 |
|
1,623 |
1,491 |
$57K |
| J7060 |
5% dextrose/water (500 ml = 1 unit) |
5,037 |
2,629 |
$57K |
| 86701 |
|
5,833 |
4,801 |
$57K |
| 87661 |
Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe |
2,187 |
2,070 |
$56K |
| 76885 |
|
252 |
240 |
$56K |
| 82043 |
|
10,869 |
10,086 |
$56K |
| 84134 |
|
4,700 |
3,986 |
$56K |
| 83520 |
|
2,623 |
2,333 |
$55K |
| 58300 |
|
135 |
105 |
$55K |
| 51701 |
|
815 |
746 |
$55K |
| J1453 |
Injection, fosaprepitant, 1 mg |
185 |
119 |
$55K |
| J1050 |
Injection, medroxyprogesterone acetate, 1 mg |
1,035 |
969 |
$55K |
| J3475 |
Injection, magnesium sulfate, per 500 mg |
15,584 |
8,282 |
$54K |
| 93786 |
|
442 |
429 |
$54K |
| 99153 |
Mod sedat endo service >5yrs |
5,372 |
4,445 |
$54K |
| G2066 |
Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results |
2,209 |
1,859 |
$54K |
| 83540 |
|
10,156 |
9,464 |
$53K |
| 93356 |
|
1,176 |
920 |
$53K |
| 87181 |
|
3,014 |
2,617 |
$53K |
| G0108 |
Diabetes outpatient self-management training services, individual, per 30 minutes |
1,154 |
994 |
$53K |
| 86317 |
|
910 |
818 |
$52K |
| 82248 |
|
9,148 |
7,121 |
$52K |
| 82533 |
|
3,087 |
2,673 |
$52K |
| 82024 |
|
1,450 |
1,309 |
$51K |
| G0260 |
Injection procedure for sacroiliac joint; provision of anesthetic, steroid and/or other therapeutic agent, with or without arthrography |
104 |
99 |
$51K |
| 90739 |
|
496 |
463 |
$50K |
| 83993 |
|
2,822 |
2,602 |
$50K |
| 86592 |
|
11,710 |
10,576 |
$49K |
| 90632 |
|
1,004 |
905 |
$49K |
| 84402 |
|
2,294 |
2,134 |
$49K |
| 84550 |
|
10,485 |
8,870 |
$49K |
| J1650 |
Injection, enoxaparin sodium, 10 mg |
20,915 |
6,028 |
$49K |
| A9500 |
Technetium tc-99m sestamibi, diagnostic, per study dose |
1,170 |
993 |
$48K |
| 88309 |
|
399 |
305 |
$48K |
| 86945 |
|
906 |
400 |
$48K |
| 90620 |
|
1,203 |
1,178 |
$48K |
| 82977 |
|
7,865 |
6,372 |
$48K |
| 64400 |
|
246 |
217 |
$47K |
| 84480 |
|
3,742 |
3,488 |
$47K |
| 93451 |
|
28 |
25 |
$46K |
| J3370 |
Injection, vancomycin hcl, 500 mg |
8,465 |
4,470 |
$46K |
| C1753 |
Catheter, intravascular ultrasound |
728 |
546 |
$46K |
| 84153 |
|
3,113 |
2,814 |
$46K |
| 82785 |
|
2,811 |
2,545 |
$46K |
| 95117 |
|
2,574 |
1,094 |
$46K |
| 88311 |
|
2,544 |
2,123 |
$45K |
| 88333 |
|
758 |
634 |
$45K |
| 63030 |
|
13 |
12 |
$45K |
| J1610 |
Injection, glucagon hydrochloride, per 1 mg |
509 |
427 |
$45K |
| 82803 |
|
1,865 |
1,439 |
$44K |
| 86870 |
|
751 |
633 |
$44K |
| 87341 |
|
5,233 |
4,731 |
$43K |
| 93798 |
|
911 |
198 |
$43K |
| 85347 |
|
1,922 |
1,475 |
$43K |
| 87116 |
|
2,984 |
2,435 |
$41K |
| 85520 |
|
1,921 |
1,493 |
$41K |
| 87147 |
|
5,191 |
4,624 |
$41K |
| 97113 |
|
378 |
113 |
$40K |
| 96111 |
|
345 |
324 |
$40K |
| J8540 |
Dexamethasone, oral, 0.25 mg |
17,232 |
10,737 |
$40K |
| 93299 |
|
1,202 |
1,135 |
$39K |
| 80143 |
|
2,202 |
1,866 |
$39K |
| 0296T |
|
528 |
477 |
$39K |
| 36590 |
|
42 |
38 |
$39K |
| 31628 |
|
93 |
66 |
$38K |
| 85046 |
|
6,791 |
5,608 |
$38K |
| J1644 |
Injection, heparin sodium, per 1000 units |
21,841 |
8,020 |
$38K |
| 86431 |
|
7,580 |
7,024 |
$38K |
| 83498 |
|
1,531 |
1,443 |
$38K |
| J3480 |
Injection, potassium chloride, per 2 meq |
6,217 |
2,626 |
$37K |
| 81508 |
|
943 |
790 |
$37K |
| A0429 |
Ambulance service, basic life support, emergency transport (bls-emergency) |
605 |
517 |
$37K |
| 85007 |
|
7,735 |
5,566 |
$37K |
| V2632 |
Posterior chamber intraocular lens |
407 |
329 |
$37K |
| 82140 |
|
2,452 |
2,049 |
$37K |
| Q0163 |
Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen |
5,418 |
3,866 |
$37K |
| 77280 |
|
159 |
120 |
$36K |
| J2930 |
Injection, methylprednisolone sodium succinate, up to 125 mg |
3,660 |
2,821 |
$36K |
| J3301 |
Injection, triamcinolone acetonide, not otherwise specified, 10 mg |
4,313 |
3,888 |
$36K |
| 99292 |
|
46 |
34 |
$35K |
| 97750 |
|
769 |
625 |
$35K |
| 27447 |
|
16 |
12 |
$34K |
| 80179 |
|
2,011 |
1,722 |
$34K |
| 29515 |
|
404 |
343 |
$34K |
| 43247 |
|
31 |
25 |
$34K |
| G0121 |
Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk |
39 |
39 |
$34K |
| 86301 |
|
1,855 |
1,642 |
$33K |
| 72195 |
|
66 |
63 |
$33K |
| 60240 |
|
21 |
12 |
$33K |
| 87075 |
|
1,829 |
1,537 |
$33K |
| 85576 |
|
1,096 |
876 |
$33K |
| 82010 |
|
3,578 |
2,891 |
$33K |
| C9463 |
Injection, aprepitant, 1 mg |
148 |
94 |
$32K |
| 82627 |
|
1,704 |
1,597 |
$32K |
| G0283 |
Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care |
915 |
403 |
$32K |
| 74455 |
|
125 |
121 |
$32K |
| 73650 |
|
453 |
346 |
$32K |
| 43275 |
|
34 |
25 |
$32K |
| 84305 |
|
1,638 |
1,548 |
$32K |
| 36500 |
|
32 |
24 |
$32K |
| C8929 |
Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography |
72 |
54 |
$31K |
| 97035 |
|
1,018 |
429 |
$31K |
| 84165 |
|
3,688 |
3,304 |
$31K |
| J1950 |
Injection, leuprolide acetate (for depot suspension), per 3.75 mg |
12 |
12 |
$31K |
| 83519 |
|
1,751 |
1,628 |
$31K |
| J9190 |
Injection, fluorouracil, 500 mg |
1,580 |
686 |
$31K |
| 87184 |
|
3,879 |
3,446 |
$31K |
| 90732 |
|
562 |
488 |
$31K |
| J1030 |
Injection, methylprednisolone acetate, 40 mg |
2,880 |
2,581 |
$31K |
| G0009 |
Administration of pneumococcal vaccine |
2,213 |
2,029 |
$30K |
| D2391 |
Resin-based composite - one surface, posterior, primary or permanent |
151 |
87 |
$30K |
| 76604 |
|
514 |
453 |
$29K |
| Q5121 |
Injection, infliximab-axxq, biosimilar, (avsola), 10 mg |
15 |
12 |
$29K |
| 76982 |
|
479 |
395 |
$29K |
| 84450 |
|
5,240 |
4,393 |
$29K |
| 82950 |
|
6,230 |
5,823 |
$29K |
| 84460 |
|
5,343 |
4,502 |
$29K |
| 94760 |
|
2,714 |
2,018 |
$28K |
| 77062 |
|
560 |
479 |
$28K |
| 90647 |
|
3,847 |
3,620 |
$28K |
| 85384 |
|
2,280 |
1,770 |
$28K |
| 97802 |
|
1,075 |
1,012 |
$27K |
| J3240 |
Injection, thyrotropin alpha, 0.9 mg, provided in 1.1 mg vial |
26 |
12 |
$27K |
| 80164 |
|
2,143 |
1,774 |
$27K |
| 97803 |
|
1,270 |
1,173 |
$27K |
| 82150 |
|
4,107 |
3,645 |
$27K |
| 88237 |
|
282 |
235 |
$27K |
| 20600 |
|
120 |
99 |
$27K |
| 97014 |
|
807 |
336 |
$27K |
| 83921 |
|
1,615 |
1,481 |
$27K |
| 99499 |
|
65 |
56 |
$27K |
| 84446 |
|
2,517 |
2,295 |
$27K |
| 86039 |
|
3,075 |
2,805 |
$26K |
| 84132 |
|
4,961 |
3,765 |
$26K |
| 69631 |
|
13 |
12 |
$26K |
| 96138 |
|
529 |
465 |
$26K |
| 84425 |
|
1,612 |
1,513 |
$25K |
| 91322 |
|
363 |
345 |
$25K |
| 71271 |
|
1,062 |
966 |
$25K |
| 86341 |
|
566 |
517 |
$24K |
| 90791 |
Psychiatric diagnostic evaluation |
687 |
615 |
$24K |
| 84030 |
|
4,489 |
1,823 |
$24K |
| 90636 |
|
327 |
298 |
$24K |
| 80177 |
|
2,086 |
1,885 |
$24K |
| 11981 |
|
164 |
142 |
$23K |
| J3473 |
Injection, hyaluronidase, recombinant, 1 usp unit |
894 |
777 |
$23K |
| A9541 |
Technetium tc-99m sulfur colloid, diagnostic, per study dose, up to 20 millicuries |
274 |
264 |
$23K |
| 87206 |
|
2,817 |
2,290 |
$23K |
| 74241 |
|
95 |
86 |
$23K |
| 94621 |
|
54 |
53 |
$23K |
| 83883 |
|
1,519 |
1,339 |
$23K |
| 87338 |
|
1,653 |
1,565 |
$23K |
| 86334 |
|
1,391 |
1,250 |
$23K |
| 92597 |
|
384 |
311 |
$22K |
| 85240 |
|
1,160 |
1,050 |
$22K |
| 85004 |
|
4,193 |
3,188 |
$22K |
| D2330 |
|
79 |
53 |
$22K |
| 29883 |
|
29 |
25 |
$22K |
| 46600 |
|
109 |
96 |
$22K |
| 64644 |
|
90 |
69 |
$22K |
| 84234 |
|
420 |
386 |
$22K |
| 77075 |
|
122 |
99 |
$22K |
| 88280 |
|
976 |
806 |
$22K |
| 70490 |
|
60 |
58 |
$22K |
| 82948 |
|
2,161 |
1,671 |
$22K |
| 85018 |
|
6,001 |
5,194 |
$21K |
| 64483 |
|
14 |
12 |
$21K |
| 82104 |
|
1,798 |
1,641 |
$21K |
| 84157 |
|
3,862 |
2,635 |
$21K |
| 86256 |
|
2,073 |
1,866 |
$21K |
| 31579 |
|
69 |
62 |
$21K |
| 85014 |
|
5,848 |
4,848 |
$21K |
| C1758 |
Catheter, ureteral |
1,550 |
1,235 |
$21K |
| 82103 |
|
1,884 |
1,720 |
$21K |
| 84590 |
|
2,344 |
2,139 |
$21K |
| 88275 |
|
137 |
105 |
$21K |
| 84270 |
|
1,100 |
1,019 |
$20K |
| 97018 |
|
1,218 |
560 |
$20K |
| 90734 |
|
2,994 |
2,931 |
$20K |
| 70545 |
|
44 |
36 |
$20K |
| 81479 |
Unlisted molecular pathology procedure |
226 |
181 |
$20K |
| J2370 |
Injection, phenylephrine hcl, up to 1 ml |
6,354 |
4,606 |
$20K |
| 82088 |
|
592 |
541 |
$20K |
| 86665 |
|
762 |
696 |
$19K |
| 83021 |
|
1,070 |
912 |
$19K |
| 85246 |
|
893 |
830 |
$19K |
| L3808 |
Wrist hand finger orthosis, rigid without joints, may include soft interface material; straps, custom fabricated, includes fitting and adjustment |
265 |
238 |
$19K |
| 20552 |
|
106 |
96 |
$19K |
| 90746 |
|
554 |
504 |
$19K |
| 84080 |
|
2,054 |
1,853 |
$18K |
| 88264 |
|
199 |
167 |
$18K |
| 93978 |
|
79 |
69 |
$18K |
| 84244 |
|
984 |
906 |
$18K |
| 87220 |
|
3,010 |
2,452 |
$18K |
| G0103 |
Prostate cancer screening; prostate specific antigen test (psa) |
1,374 |
1,262 |
$18K |
| 96402 |
|
267 |
190 |
$18K |
| S5102 |
Day care services, adult; per diem |
159 |
47 |
$17K |
| J0295 |
Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm |
5,225 |
2,061 |
$17K |
| J2543 |
Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) |
6,176 |
2,253 |
$17K |
| 86709 |
|
2,580 |
2,318 |
$17K |
| 30520 |
|
12 |
12 |
$17K |
| J9263 |
Injection, oxaliplatin, 0.5 mg |
599 |
350 |
$17K |
| 81596 |
|
457 |
428 |
$17K |
| 96523 |
|
423 |
285 |
$16K |
| 93243 |
|
169 |
132 |
$16K |
| 83020 |
|
1,562 |
1,316 |
$16K |
| 29105 |
|
196 |
184 |
$16K |
| J9370 |
Vincristine sulfate, 1 mg |
2,593 |
1,762 |
$16K |
| 87285 |
|
2,259 |
2,073 |
$16K |
| J3489 |
Injection, zoledronic acid, 1 mg |
712 |
612 |
$16K |
| J9060 |
Injection, cisplatin, powder or solution, 10 mg |
1,183 |
535 |
$16K |
| 99406 |
|
1,810 |
1,688 |
$16K |
| 20551 |
|
137 |
123 |
$16K |
| 91321 |
|
338 |
337 |
$16K |
| 80158 |
|
1,228 |
740 |
$16K |
| 82247 |
|
2,430 |
1,903 |
$16K |
| 93242 |
|
237 |
223 |
$15K |
| Q9958 |
High osmolar contrast material, up to 149 mg/ml iodine concentration, per ml |
535 |
485 |
$15K |
| 87493 |
|
621 |
564 |
$15K |
| A9503 |
Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries |
532 |
488 |
$15K |
| 82390 |
|
1,676 |
1,541 |
$15K |
| 85097 |
|
122 |
104 |
$15K |
| J1790 |
Injection, droperidol, up to 5 mg |
6,235 |
5,365 |
$15K |
| 87106 |
|
1,451 |
1,287 |
$15K |
| 86705 |
|
2,744 |
2,486 |
$15K |
| 84481 |
|
1,015 |
936 |
$15K |
| A4565 |
Slings |
620 |
500 |
$15K |
| 90381 |
|
97 |
97 |
$15K |
| 76377 |
|
110 |
91 |
$15K |
| 82397 |
|
987 |
904 |
$15K |
| J1200 |
Injection, diphenhydramine hcl, up to 50 mg |
12,405 |
9,555 |
$15K |
| 82523 |
|
1,342 |
1,172 |
$15K |
| J0780 |
Injection, prochlorperazine, up to 10 mg |
3,979 |
3,148 |
$15K |
| J2550 |
Injection, promethazine hcl, up to 50 mg |
7,520 |
5,273 |
$15K |
| 81015 |
|
2,974 |
2,644 |
$15K |
| D7240 |
Removal of impacted tooth - completely bony |
14 |
13 |
$15K |
| 95012 |
|
487 |
451 |
$14K |
| J9171 |
Injection, docetaxel, 1 mg |
143 |
99 |
$14K |
| J1815 |
Injection, insulin, per 5 units |
14,704 |
3,825 |
$14K |
| 82075 |
|
673 |
569 |
$14K |
| 90834 |
Psychotherapy, 45 minutes with patient |
1,552 |
1,198 |
$14K |
| 69421 |
|
14 |
13 |
$14K |
| 43276 |
|
17 |
16 |
$14K |
| 84295 |
|
3,499 |
2,711 |
$14K |
| A9609 |
Fludeoxyglucose f18 up to 15 millicuries |
277 |
249 |
$14K |
| 87210 |
|
1,595 |
1,245 |
$14K |
| C1751 |
Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis) |
91 |
62 |
$14K |
| D1351 |
Sealant - per tooth |
55 |
27 |
$13K |
| 87641 |
|
399 |
364 |
$13K |
| J2765 |
Injection, metoclopramide hcl, up to 10 mg |
5,953 |
4,854 |
$13K |
| 86696 |
|
924 |
852 |
$13K |
| 64616 |
|
38 |
26 |
$13K |
| 93246 |
|
222 |
205 |
$13K |
| 97163 |
|
193 |
153 |
$13K |
| 96113 |
|
416 |
369 |
$13K |
| J2357 |
Injection, omalizumab, 5 mg |
62 |
38 |
$13K |
| 97542 |
|
267 |
185 |
$13K |
| 74430 |
|
69 |
64 |
$13K |
| 87177 |
|
1,224 |
1,106 |
$13K |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
11,209 |
8,404 |
$12K |
| J9201 |
Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg |
831 |
387 |
$12K |
| 71552 |
|
12 |
12 |
$12K |
| 86777 |
|
1,142 |
946 |
$12K |
| 82164 |
|
923 |
855 |
$12K |
| 90710 |
|
3,870 |
3,783 |
$12K |
| 77061 |
|
428 |
350 |
$12K |
| 86308 |
|
1,419 |
1,333 |
$12K |
| G0010 |
Administration of hepatitis b vaccine |
679 |
617 |
$12K |
| 88271 |
|
134 |
104 |
$11K |
| 90716 |
|
1,664 |
1,628 |
$11K |
| 90681 |
|
5,295 |
5,137 |
$11K |
| 83525 |
|
998 |
950 |
$11K |
| 82085 |
|
1,251 |
1,137 |
$11K |
| L3933 |
Finger orthosis, without joints, may include soft interface, custom fabricated, includes fitting and adjustment |
200 |
176 |
$11K |
| 82525 |
|
1,077 |
969 |
$11K |
| 80230 |
|
119 |
113 |
$11K |
| 83704 |
|
341 |
311 |
$11K |
| 69210 |
|
44 |
41 |
$11K |
| 87640 |
|
396 |
384 |
$11K |
| 82435 |
|
2,251 |
1,860 |
$11K |
| 86695 |
|
924 |
852 |
$11K |
| 83521 |
|
547 |
499 |
$11K |
| 90792 |
Psychiatric diagnostic evaluation with medical services |
582 |
520 |
$11K |
| 82040 |
|
2,234 |
2,029 |
$10K |
| J1953 |
Injection, levetiracetam, 10 mg |
2,196 |
1,586 |
$10K |
| 0399T |
|
352 |
284 |
$10K |
| 87511 |
|
356 |
344 |
$10K |
| 86644 |
|
784 |
687 |
$10K |
| 87176 |
|
1,205 |
985 |
$10K |
| 93926 |
|
52 |
49 |
$10K |
| 89230 |
|
185 |
129 |
$10K |
| 84207 |
|
468 |
440 |
$10K |
| 82232 |
|
643 |
569 |
$10K |
| 77077 |
|
164 |
133 |
$10K |
| J1642 |
Injection, heparin sodium, (heparin lock flush), per 10 units |
13,139 |
7,305 |
$9K |
| 93925 |
|
48 |
39 |
$9K |
| 86769 |
|
339 |
308 |
$9K |
| 29086 |
|
102 |
87 |
$9K |
| A6212 |
Foam dressing, wound cover, sterile, pad size 16 sq. in. or less, with any size adhesive border, each dressing |
2,262 |
1,900 |
$9K |
| 83937 |
|
504 |
461 |
$9K |
| 84182 |
|
163 |
150 |
$9K |
| 78709 |
|
15 |
13 |
$9K |
| 73522 |
|
79 |
65 |
$9K |
| 81206 |
|
94 |
83 |
$9K |
| 74330 |
|
50 |
44 |
$9K |
| 73070 |
|
193 |
163 |
$9K |
| 64643 |
|
54 |
50 |
$9K |
| D2392 |
Resin-based composite - two surfaces, posterior, primary or permanent |
36 |
25 |
$9K |
| G0109 |
Diabetes outpatient self-management training services, group session (2 or more), per 30 minutes |
232 |
216 |
$9K |
| 80299 |
|
483 |
426 |
$9K |
| 85245 |
|
467 |
438 |
$9K |
| 41874 |
|
31 |
12 |
$9K |
| 96139 |
|
94 |
74 |
$8K |
| 84252 |
|
479 |
471 |
$8K |
| G0451 |
Development testing, with interpretation and report, per standardized instrument form |
202 |
199 |
$8K |
| 83721 |
|
2,152 |
2,062 |
$8K |
| 86612 |
|
534 |
493 |
$8K |
| 83010 |
|
581 |
439 |
$8K |
| 70360 |
|
101 |
93 |
$8K |
| 82945 |
|
1,733 |
1,553 |
$8K |
| 90461 |
|
3,189 |
2,941 |
$8K |
| 86698 |
|
280 |
242 |
$8K |
| 86364 |
|
2,463 |
2,399 |
$8K |
| 87015 |
|
1,465 |
1,047 |
$8K |
| 87901 |
|
33 |
30 |
$8K |
| J9000 |
Injection, doxorubicin hydrochloride, 10 mg |
355 |
218 |
$8K |
| 85613 |
|
906 |
810 |
$8K |
| 96133 |
|
116 |
97 |
$8K |
| 95165 |
Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy, multiple dose vials |
15 |
14 |
$8K |
| 77332 |
|
39 |
24 |
$8K |
| A9520 |
Technetium tc-99m tilmanocept, diagnostic, up to 0.5 millicuries |
27 |
26 |
$8K |
| 85049 |
|
1,205 |
789 |
$7K |
| 86787 |
|
685 |
646 |
$7K |
| 74022 |
|
85 |
72 |
$7K |
| 70544 |
|
14 |
13 |
$7K |
| J9206 |
Injection, irinotecan, 20 mg |
298 |
157 |
$7K |
| 82310 |
|
1,340 |
1,166 |
$7K |
| G8989 |
Self care functional limitation, discharge status, at discharge from therapy or to end reporting |
193 |
142 |
$7K |
| 87350 |
|
688 |
641 |
$7K |
| H2017 |
Psychosocial rehabilitation services, per 15 minutes |
82 |
38 |
$7K |
| 87385 |
|
487 |
449 |
$7K |
| 69209 |
|
60 |
49 |
$7K |
| 82810 |
|
470 |
385 |
$7K |
| 75809 |
|
58 |
54 |
$7K |
| 86593 |
|
1,689 |
1,562 |
$7K |
| 76886 |
|
40 |
35 |
$7K |
| 20605 |
|
29 |
24 |
$7K |
| C9113 |
Injection, pantoprazole sodium, per vial |
2,410 |
1,222 |
$7K |
| C1730 |
Catheter, electrophysiology, diagnostic, other than 3d mapping (19 or fewer electrodes) |
19 |
13 |
$7K |
| J1020 |
Injection, methylprednisolone acetate, 20 mg |
649 |
601 |
$7K |
| J1580 |
Injection, garamycin, gentamicin, up to 80 mg |
1,554 |
1,039 |
$7K |
| J3411 |
Injection, thiamine hcl, 100 mg |
1,854 |
972 |
$7K |
| 83835 |
|
459 |
427 |
$7K |
| 86694 |
|
509 |
474 |
$6K |
| 86707 |
|
632 |
584 |
$6K |
| 86682 |
|
627 |
580 |
$6K |
| 90837 |
Psychotherapy, 53 minutes with patient |
1,254 |
950 |
$6K |
| 73010 |
|
73 |
57 |
$6K |
| 97167 |
|
75 |
62 |
$6K |
| 89050 |
|
722 |
561 |
$6K |
| L3913 |
Hand finger orthosis, without joints, may include soft interface, straps, custom fabricated, includes fitting and adjustment |
84 |
76 |
$6K |
| 82787 |
|
365 |
341 |
$6K |
| 82139 |
|
349 |
290 |
$6K |
| G0297 |
Low dose ct scan (ldct) for lung cancer screening |
278 |
265 |
$6K |
| 73503 |
|
56 |
53 |
$6K |
| A0428 |
Ambulance service, basic life support, non-emergency transport, (bls) |
1,266 |
788 |
$6K |
| 82340 |
|
1,173 |
1,047 |
$6K |
| A9270 |
Non-covered item or service |
7,805 |
4,538 |
$6K |
| 81243 |
|
142 |
120 |
$6K |
| 90662 |
|
586 |
476 |
$6K |
| 86381 |
|
470 |
443 |
$6K |
| J2920 |
Injection, methylprednisolone sodium succinate, up to 40 mg |
1,656 |
1,286 |
$6K |
| 16020 |
|
44 |
41 |
$6K |
| J0461 |
Injection, atropine sulfate, 0.01 mg |
1,517 |
1,171 |
$6K |
| J9074 |
Injection, cyclophosphamide (sandoz), 5 mg |
33 |
18 |
$6K |
| 84155 |
|
2,414 |
2,129 |
$6K |
| 80171 |
|
311 |
293 |
$5K |
| 43244 |
|
12 |
12 |
$5K |
| 82951 |
|
443 |
411 |
$5K |
| 86331 |
|
365 |
348 |
$5K |
| 90707 |
|
1,278 |
1,253 |
$5K |
| 78999 |
|
18 |
15 |
$5K |
| J1010 |
Injection, methylprednisolone acetate, 1 mg |
586 |
541 |
$5K |
| 86606 |
|
270 |
233 |
$5K |
| 78300 |
|
13 |
12 |
$5K |
| 86403 |
|
576 |
512 |
$5K |
| 0081A |
|
208 |
203 |
$5K |
| 87305 |
|
485 |
246 |
$5K |
| 84520 |
|
1,361 |
884 |
$5K |
| 72080 |
|
44 |
38 |
$5K |
| L0172 |
Cervical, collar, semi-rigid thermoplastic foam, two-piece, prefabricated, off-the-shelf |
295 |
173 |
$5K |
| 76506 |
|
27 |
26 |
$5K |
| 97033 |
|
149 |
65 |
$5K |
| 90480 |
|
399 |
387 |
$5K |
| 91010 |
|
13 |
12 |
$5K |
| J0360 |
Injection, hydralazine hcl, up to 20 mg |
1,820 |
1,318 |
$5K |
| 82365 |
|
453 |
386 |
$5K |
| L1832 |
Knee orthosis, adjustable knee joints (unicentric or polycentric), positional orthosis, rigid support, prefabricated item that has been trimmed, bent, molded, assembled, or otherwise customized to fit a specific patient by an individual with expertise |
138 |
108 |
$5K |
| 86905 |
|
60 |
54 |
$5K |
| 84630 |
|
571 |
519 |
$5K |
| 84597 |
|
449 |
422 |
$5K |
| D2331 |
|
25 |
15 |
$5K |
| 80349 |
|
270 |
263 |
$5K |
| 86635 |
|
245 |
209 |
$5K |
| 98927 |
|
274 |
241 |
$5K |
| Q0177 |
Hydroxyzine pamoate, 25 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen |
4,218 |
3,139 |
$5K |
| 74175 |
|
17 |
15 |
$5K |
| 87071 |
|
483 |
374 |
$4K |
| 51702 |
|
61 |
53 |
$4K |
| 86258 |
|
318 |
312 |
$4K |
| 98929 |
|
222 |
204 |
$4K |
| 87481 |
|
35 |
35 |
$4K |
| A9551 |
Technetium tc-99m succimer, diagnostic, per study dose, up to 10 millicuries |
16 |
15 |
$4K |
| P9041 |
Infusion, albumin (human), 5%, 50 ml |
84 |
58 |
$4K |
| Q9966 |
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml |
1,008 |
889 |
$4K |
| 84300 |
|
882 |
734 |
$4K |
| 71101 |
|
30 |
28 |
$4K |
| 43249 |
|
17 |
12 |
$4K |
| M0245 |
Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring |
13 |
13 |
$4K |
| 96127 |
|
430 |
417 |
$4K |
| J0665 |
Injection, bupivicaine, not otherwise specified, 0.5 mg |
3,137 |
2,857 |
$4K |
| 86021 |
|
276 |
240 |
$4K |
| A9562 |
Technetium tc-99m mertiatide, diagnostic, per study dose, up to 15 millicuries |
12 |
12 |
$4K |
| 96130 |
|
94 |
86 |
$4K |
| H0038 |
Self-help/peer services, per 15 minutes |
39 |
13 |
$4K |
| 82657 |
|
173 |
160 |
$4K |
| 11102 |
|
28 |
28 |
$4K |
| 87905 |
|
309 |
294 |
$4K |
| J2310 |
Injection, naloxone hydrochloride, per 1 mg |
304 |
232 |
$4K |
| 90380 |
|
45 |
42 |
$3K |
| T1017 |
Targeted case management, each 15 minutes |
63 |
45 |
$3K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
5,037 |
4,485 |
$3K |
| 76981 |
|
59 |
57 |
$3K |
| C2625 |
Stent, non-coronary, temporary, with delivery system |
16 |
13 |
$3K |
| 11104 |
|
14 |
13 |
$3K |
| 84681 |
|
186 |
178 |
$3K |
| 86036 |
|
407 |
389 |
$3K |
| 10022 |
|
15 |
12 |
$3K |
| 12013 |
|
28 |
27 |
$3K |
| 81050 |
|
786 |
676 |
$3K |
| J1956 |
Injection, levofloxacin, 250 mg |
1,938 |
1,560 |
$3K |
| 86363 |
|
98 |
87 |
$3K |
| 99407 |
|
246 |
238 |
$3K |
| 82955 |
|
458 |
396 |
$3K |
| 84478 |
|
429 |
270 |
$3K |
| 64405 |
|
12 |
12 |
$3K |
| 85660 |
|
492 |
394 |
$3K |
| 90633 |
|
5,964 |
5,839 |
$3K |
| 90696 |
|
2,464 |
2,428 |
$3K |
| J2060 |
Injection, lorazepam, 2 mg |
4,515 |
3,363 |
$3K |
| 80175 |
|
269 |
251 |
$3K |
| 17250 |
|
28 |
25 |
$3K |
| 81220 |
CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants |
18 |
13 |
$3K |
| 87209 |
|
223 |
207 |
$3K |
| 97760 |
|
73 |
53 |
$3K |
| 97168 |
|
95 |
82 |
$3K |
| J7510 |
Prednisolone oral, per 5 mg |
1,488 |
1,206 |
$3K |
| 88344 |
|
15 |
12 |
$3K |
| 96132 |
|
30 |
28 |
$3K |
| 86352 |
|
16 |
14 |
$3K |
| 20526 |
|
14 |
13 |
$3K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
28 |
27 |
$3K |
| 86922 |
|
50 |
38 |
$3K |
| J7512 |
Prednisone, immediate release or delayed release, oral, 1 mg |
5,011 |
2,906 |
$3K |
| J1040 |
Injection, methylprednisolone acetate, 80 mg |
369 |
341 |
$3K |
| J0692 |
Injection, cefepime hydrochloride, 500 mg |
729 |
213 |
$3K |
| J7070 |
Infusion, d5w, 1000 cc |
19 |
13 |
$3K |
| 93750 |
|
31 |
14 |
$2K |
| 96137 |
|
81 |
70 |
$2K |
| 80325 |
|
127 |
121 |
$2K |
| 82180 |
|
333 |
314 |
$2K |
| 86141 |
|
200 |
191 |
$2K |
| 90700 |
|
2,375 |
2,321 |
$2K |
| 76983 |
|
100 |
87 |
$2K |
| 99151 |
|
136 |
131 |
$2K |
| J0688 |
Injection, cefazolin sodium (hikma), not therapeutically equivalent to j0690, 500 mg |
3,232 |
2,501 |
$2K |
| 86645 |
|
133 |
129 |
$2K |
| 86008 |
|
101 |
101 |
$2K |
| 76098 |
|
18 |
12 |
$2K |
| 82270 |
|
513 |
465 |
$2K |
| 80346 |
|
125 |
116 |
$2K |
| J2919 |
Injection, methylprednisolone sodium succinate, 5 mg |
567 |
453 |
$2K |
| 85612 |
|
134 |
132 |
$2K |
| 83789 |
|
138 |
113 |
$2K |
| 84466 |
|
189 |
176 |
$2K |
| G0237 |
Therapeutic procedures to increase strength or endurance of respiratory muscles, face to face, one on one, each 15 minutes (includes monitoring) |
67 |
41 |
$2K |
| J1630 |
Injection, haloperidol, up to 5 mg |
907 |
688 |
$2K |
| 86162 |
|
114 |
103 |
$2K |
| J1940 |
Injection, furosemide, up to 20 mg |
2,097 |
1,433 |
$2K |
| J0137 |
Injection, acetaminophen (hikma), not therapeutically equivalent to j0131, 10 mg |
791 |
708 |
$2K |
| 88365 |
|
26 |
25 |
$2K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
112 |
101 |
$2K |
| 29065 |
|
13 |
13 |
$2K |
| 84075 |
|
452 |
402 |
$2K |
| L4350 |
Ankle control orthosis, stirrup style, rigid, includes any type interface (e.g., pneumatic, gel), prefabricated, off-the-shelf |
265 |
218 |
$2K |
| J1171 |
Injection, hydromorphone, 0.1 mg |
809 |
527 |
$2K |
| 36600 |
|
68 |
59 |
$2K |
| 90698 |
|
974 |
949 |
$2K |
| T1016 |
Case management, each 15 minutes |
29 |
16 |
$2K |
| J2272 |
Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg |
1,420 |
1,172 |
$2K |
| 82952 |
|
443 |
411 |
$2K |
| 88262 |
|
14 |
14 |
$2K |
| J2003 |
Injection, lidocaine hydrochloride, 1 mg |
2,385 |
1,855 |
$2K |
| 96131 |
|
37 |
36 |
$2K |
| 36416 |
|
281 |
257 |
$2K |
| 84591 |
|
158 |
108 |
$2K |
| 0556T |
|
46 |
38 |
$2K |
| 86053 |
|
34 |
32 |
$1K |
| 96377 |
|
82 |
51 |
$1K |
| J0694 |
Injection, cefoxitin sodium, 1 gm |
328 |
141 |
$1K |
| 80203 |
|
130 |
123 |
$1K |
| 88230 |
|
12 |
12 |
$1K |
| 90656 |
|
336 |
336 |
$1K |
| 94761 |
|
50 |
47 |
$1K |
| 95970 |
|
13 |
12 |
$1K |
| 83003 |
|
78 |
72 |
$1K |
| 80348 |
|
57 |
51 |
$1K |
| S5170 |
Home delivered meals, including preparation; per meal |
25 |
25 |
$1K |
| 87449 |
|
105 |
81 |
$1K |
| J2371 |
Injection, phenylephrine hydrochloride, 20 micrograms |
1,879 |
1,646 |
$1K |
| 80183 |
|
117 |
110 |
$1K |
| 90853 |
Group psychotherapy (other than of a multiple-family group) |
577 |
318 |
$1K |
| J7042 |
5% dextrose/normal saline (500 ml = 1 unit) |
419 |
329 |
$1K |
| G8979 |
Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting |
1,117 |
876 |
$1K |
| 82017 |
|
69 |
64 |
$1K |
| 85390 |
|
17 |
12 |
$1K |
| 80353 |
|
54 |
52 |
$1K |
| 88334 |
|
47 |
41 |
$1K |
| 83930 |
|
212 |
181 |
$1K |
| S5161 |
Emergency response system; service fee, per month (excludes installation and testing) |
410 |
409 |
$1K |
| 86765 |
|
129 |
124 |
$1K |
| J9250 |
Methotrexate sodium, 5 mg |
920 |
504 |
$1K |
| 90733 |
|
16 |
15 |
$1K |
| 86880 |
|
68 |
61 |
$1K |
| 87512 |
|
40 |
40 |
$1K |
| 96136 |
|
82 |
71 |
$1K |
| 80354 |
|
63 |
60 |
$1K |
| 83090 |
|
54 |
51 |
$1K |
| 85549 |
|
56 |
54 |
$970.47 |
| G9171 |
Voice functional limitation, current status at therapy episode outset and at reporting intervals |
297 |
203 |
$965.33 |
| J1805 |
Injection, esmolol hydrochloride, 10 mg |
208 |
181 |
$951.36 |
| 82595 |
|
157 |
144 |
$950.69 |
| 84445 |
|
28 |
26 |
$919.08 |
| 86735 |
|
101 |
97 |
$907.36 |
| 90680 |
|
14 |
14 |
$882.03 |
| 85300 |
|
84 |
63 |
$814.85 |
| 87185 |
|
172 |
152 |
$811.14 |
| 82172 |
|
50 |
39 |
$794.82 |
| J1920 |
Injection, labetalol hydrochloride, 5 mg |
414 |
329 |
$794.02 |
| G8980 |
Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting |
309 |
247 |
$786.56 |
| 90832 |
Psychotherapy, 30 minutes with patient |
277 |
216 |
$768.17 |
| G8985 |
Carrying, moving and handling objects, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting |
297 |
248 |
$759.68 |
| J0736 |
Injection, clindamycin phosphate, 300 mg |
125 |
102 |
$708.63 |
| P9045 |
Infusion, albumin (human), 5%, 250 ml |
16 |
14 |
$705.29 |
| A4306 |
Disposable drug delivery system, flow rate of less than 50 ml per hour |
30 |
26 |
$692.90 |
| 82157 |
|
26 |
24 |
$679.91 |
| 94664 |
|
25 |
25 |
$677.66 |
| 86316 |
|
42 |
37 |
$640.11 |
| 29130 |
|
14 |
14 |
$638.00 |
| 82438 |
|
152 |
105 |
$626.27 |
| 80178 |
|
88 |
73 |
$622.01 |
| 84166 |
|
44 |
38 |
$612.82 |
| 80201 |
|
39 |
37 |
$608.79 |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
26 |
18 |
$608.40 |
| G8978 |
Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals |
1,221 |
888 |
$579.71 |
| 96380 |
|
137 |
134 |
$578.39 |
| 93280 |
|
15 |
13 |
$575.02 |
| 83935 |
|
99 |
91 |
$533.38 |
| 77091 |
|
43 |
38 |
$529.85 |
| J1596 |
Injection, glycopyrrolate, 0.1 mg |
978 |
847 |
$522.60 |
| J3360 |
Injection, diazepam, up to 5 mg |
33 |
25 |
$519.46 |
| 80361 |
|
20 |
20 |
$504.35 |
| J0737 |
Injection, clindamycin phosphate (baxter), not therapeutically equivalent to j0736, 300 mg |
196 |
159 |
$495.17 |
| L4360 |
Walking boot, pneumatic and/or vacuum, with or without joints, with or without interface material, prefabricated item that has been trimmed, bent, molded, assembled, or otherwise customized to fit a specific patient by an individual with expertise |
17 |
14 |
$484.95 |
| J7611 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg |
30 |
26 |
$484.05 |
| 86664 |
|
37 |
36 |
$463.08 |
| 80195 |
|
53 |
36 |
$452.11 |
| G8987 |
Self care functional limitation, current status, at therapy episode outset and at reporting intervals |
434 |
297 |
$443.56 |
| Q0164 |
Prochlorperazine maleate, 5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen |
585 |
247 |
$435.69 |
| J1626 |
Injection, granisetron hydrochloride, 100 mcg |
313 |
205 |
$412.29 |
| 84105 |
|
77 |
68 |
$390.18 |
| A9537 |
Technetium tc-99m mebrofenin, diagnostic, per study dose, up to 15 millicuries |
12 |
12 |
$389.60 |
| 86618 |
|
25 |
25 |
$386.78 |
| 0346T |
|
21 |
14 |
$386.75 |
| 90744 |
|
361 |
345 |
$383.33 |
| 99443 |
|
22 |
18 |
$375.01 |
| 85598 |
|
31 |
27 |
$361.38 |
| 85303 |
|
29 |
26 |
$354.75 |
| 92504 |
|
19 |
18 |
$353.85 |
| 84154 |
|
27 |
25 |
$353.74 |
| 80202 |
|
21 |
12 |
$346.49 |
| 86617 |
|
13 |
13 |
$335.03 |
| 98928 |
|
13 |
12 |
$332.07 |
| 96119 |
|
15 |
13 |
$329.76 |
| 80235 |
|
26 |
25 |
$325.94 |
| A9561 |
Technetium tc-99m oxidronate, diagnostic, per study dose, up to 30 millicuries |
12 |
12 |
$303.46 |
| 82375 |
|
18 |
15 |
$299.94 |
| J9260 |
Injection, methotrexate sodium, 50 mg |
144 |
91 |
$292.96 |
| 90648 |
|
1,268 |
1,242 |
$282.21 |
| J0612 |
Injection, calcium gluconate, not otherwise specified, 10 mg |
24 |
12 |
$260.00 |
| 85306 |
|
20 |
15 |
$256.87 |
| J9181 |
Injection, etoposide, 10 mg |
38 |
13 |
$254.31 |
| 82668 |
|
15 |
13 |
$250.56 |
| 83916 |
|
13 |
13 |
$247.94 |
| 86702 |
|
48 |
41 |
$243.47 |
| 86692 |
|
12 |
12 |
$241.56 |
| 86231 |
|
29 |
29 |
$235.63 |
| 84163 |
|
16 |
13 |
$233.38 |
| L1830 |
Knee orthosis, immobilizer, canvas longitudinal, prefabricated, off-the-shelf |
39 |
26 |
$230.97 |
| 84144 |
|
13 |
13 |
$226.33 |
| J0574 |
Buprenorphine/naloxone, oral, greater than 6 mg, but less than or equal to 10 mg buprenorphine |
70 |
35 |
$217.59 |
| J2470 |
Injection, pantoprazole sodium, 40 mg |
162 |
89 |
$212.63 |
| 82775 |
|
13 |
12 |
$210.70 |
| 96381 |
|
44 |
44 |
$203.16 |
| 82379 |
|
14 |
13 |
$202.44 |
| 90619 |
|
15 |
15 |
$197.57 |
| 85999 |
|
59 |
41 |
$189.75 |
| G8998 |
Swallowing functional limitation, discharge status, at discharge from therapy or to end reporting |
264 |
231 |
$168.00 |
| 83873 |
|
12 |
12 |
$152.03 |
| 82272 |
|
44 |
43 |
$147.01 |
| 87899 |
|
15 |
14 |
$145.68 |
| Q0169 |
Promethazine hydrochloride, 12.5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen |
1,088 |
741 |
$131.92 |
| G8988 |
Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting |
431 |
296 |
$125.23 |
| 86663 |
|
13 |
12 |
$124.41 |
| 82042 |
|
18 |
13 |
$123.68 |
| 98926 |
|
14 |
13 |
$108.60 |
| 86580 |
|
21 |
14 |
$102.48 |
| 88177 |
|
14 |
13 |
$98.29 |
| G8984 |
Carrying, moving & handling objects functional limitation, current status, at therapy episode outset and at reporting intervals |
301 |
245 |
$90.29 |
| J2598 |
Injection, vasopressin, 1 unit |
49 |
40 |
$82.23 |
| 90713 |
|
26 |
25 |
$76.68 |
| A0433 |
Advanced life support, level 2 (als 2) |
38 |
27 |
$66.44 |
| J1836 |
Injection, metronidazole, 10 mg |
26 |
13 |
$63.24 |
| A0426 |
Ambulance service, advanced life support, non-emergency transport, level 1 (als 1) |
20 |
12 |
$57.53 |
| 90474 |
|
24 |
24 |
$50.94 |
| J2305 |
Injection, nitroglycerin, 5 mg |
149 |
129 |
$44.21 |
| J2274 |
Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg |
21 |
16 |
$43.73 |
| G8996 |
Swallowing functional limitation, current status at therapy episode outset and at reporting intervals |
424 |
327 |
$43.35 |
| 0054A |
|
13 |
13 |
$40.03 |
| 90833 |
Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) |
16 |
13 |
$33.50 |
| J2720 |
Injection, protamine sulfate, per 10 mg |
18 |
12 |
$30.98 |
| G9174 |
Other speech language pathology functional limitation, current status at therapy episode outset and at reporting intervals |
62 |
36 |
$27.96 |
| 85008 |
|
35 |
31 |
$17.71 |
| J2469 |
Injection, palonosetron hcl, 25 mcg |
13 |
13 |
$7.74 |
| J7613 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg |
30 |
24 |
$5.92 |
| J0697 |
Injection, sterile cefuroxime sodium, per 750 mg |
14 |
12 |
$1.34 |
| G8997 |
Swallowing functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting |
406 |
321 |
$0.84 |
| Q0220 |
Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), 300 mg |
137 |
105 |
$0.00 |
| G9176 |
Other speech language pathology functional limitation, discharge status at discharge from therapy or to end reporting |
22 |
12 |
$0.00 |
| G8981 |
Changing & maintaining body position functional limitation, current status, at therapy episode outset and at reporting intervals |
39 |
26 |
$0.00 |
| G9175 |
Other speech language pathology functional limitation, projected goal status at therapy episode outset, at reporting intervals, and at discharge or to end reporting |
37 |
24 |
$0.00 |
| G9173 |
Voice functional limitation, discharge status at discharge from therapy or to end reporting |
133 |
110 |
$0.00 |
| G9172 |
Voice functional limitation, projected goal status at therapy episode outset, at reporting intervals, and at discharge or to end reporting |
238 |
194 |
$0.00 |
| G8982 |
Changing & maintaining body position functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting |
39 |
26 |
$0.00 |
| 90723 |
|
15 |
15 |
$0.00 |